Involvement of the chemokine CCL3 and the purinoceptor P2X7 in the spinal cord in paclitaxel-induced mechanical allodynia by unknown
MOLECULAR PAIN
Ochi-ishi et al. Molecular Pain 2014, 10:53
http://www.molecularpain.com/content/10/1/53RESEARCH Open AccessInvolvement of the chemokine CCL3 and the
purinoceptor P2X7 in the spinal cord in
paclitaxel-induced mechanical allodynia
Ryutaro Ochi-ishi, Kenichiro Nagata, Tomoyuki Inoue, Hidetoshi Tozaki-Saitoh, Makoto Tsuda and Kazuhide Inoue*Abstract
Background: Paclitaxel is an effective chemotherapeutic agent widely used for the treatment of solid tumors. The major
dose-limiting toxicity of paclitaxel is peripheral neuropathy. The mechanisms underlying the development and
maintenance of paclitaxel-induced peripheral neuropathy are still unclear, and there are no currently established
effective treatments. Accumulating evidence in models of neuropathic pain in which peripheral nerves are
lesioned has implicated spinal microglia and chemokines in pain hypersensitivity, but little is know about their
roles in chemotherapy-induced peripheral neuropathy. In the present study, we investigated the role of CC-chemokine
ligand 3 (CCL3) in the spinal cord in the development and maintenance of mechanical allodynia using a rat model
of paclitaxel-induced neuropathy.
Findings: Repeated intravenous administration of paclitaxel induced a marked decrease in paw withdrawal threshold
in response to mechanical stimulation (mechanical allodynia). In these rats, the number of microglia in the spinal dorsal
horn (SDH) was significantly increased. Paclitaxel-treated rats showed a significant increase in the expression of mRNAs
for CCL3 and its receptor CCR5 in the SDH. Intrathecal administration of a CCL3-neutralizing antibody not only
attenuated the development of paclitaxel-induced mechanical allodynia but also reversed its maintenance. Paclitaxel
also upregulated expression of purinoceptor P2X7 receptors (P2X7Rs), which have been implicated in the release
of CCL3 from microglia, in the SDH. The selective P2X7R antagonist A438079 had preventive and reversal effects
on paclitaxel-induced allodynia.
Conclusions: Our findings suggest a contribution of CCL3 and P2X7Rs in the SDH to paclitaxel-induced allodynia and
may provide new therapeutic targets for paclitaxel-induced painful neuropathy.
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Introduction
Paclitaxel is an effective chemotherapeutic agent widely
used for the treatment of breast, ovarian, and non-small-
cell lung cancer [1]. Paclitaxel often induces peripheral
neuropathy, which is characterized by a sensory abnor-
mality of extremities usually occurring in a stocking-
and-glove distribution in addition to motor dysfunction
in patients [2]. Peripheral neuropathy is the major
dose-limiting toxicity of paclitaxel and may persist for
months to years [3], having a long-term negative impact* Correspondence: inoue@phar.kyushu-u.ac.jp
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unless otherwise stated.on patients’ quality of life. However, the mechanisms
underlying paclitaxel-induced peripheral neuropathy re-
main unknown, and there are no established treatments.
A growing body of evidence indicates that activated
microglia in the spinal dorsal horn (SDH) play important
roles in pathological chronic pain in different animal
models [4-6]. Activated microglia produce many types of
inflammatory mediators, such as proinflammatory cyto-
kines and chemokines, which contribute to the initiation
and maintenance of pain hypersensitivity [6-8]. It was
recently reported that paclitaxel treatment induces acti-
vation of microglia in the SDH in rats and mice [9] and
that intrathecal administration of minocycline, a reagent
that can inhibit microglial activation attenuates paclitaxel-
induced pain hypersensitivity [10]. We have previouslyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ligand 3 (CCL3; also known as MIP-1α) [11] and that in a
model of spinal nerve injury, spinal CCL3 expression is
upregulated in microglia and contributes to mechanical
allodynia [12]. Furthermore, intrathecal administration of
CCL3 to naïve animals produces mechanical allodynia
[12,13]. CCL3 is known to activate its cognate receptors
CCR5 and CCR1 [14], and a pharmacological blockade of
spinal CCL3 signaling by intrathecal administration of
CCR5 antagonists reduces pain hypersensitivity after trau-
matic nerve injury [12,15]. These results suggest that
spinal CCL3 plays an important role in traumatic nerve
injury-induced allodynia. However, there are no reports
demonstrating whether CCL3 in the spinal cord contrib-
utes to chemothe rapy-induced neuropathic pain. Thus,
the aim of the present study was to investigate the role of
spinal CCL3 in mechanical allodynia using a rat model of
paclitaxel-induced neuropathy.Methods
All experimental procedures were approved by the Institu-
tional Animal Care and Use committee review panels at
Kyushu University.
Male Sprague–Dawley rats (8–11 weeks old) were ob-
tained from Japan SLC (Hamamatsu, Japan). The rats were
housed at a temperature of 22 ± 1°C with a 12-hour light–
dark cycle and had ad libitum access to food and water.
Paclitaxel (LKT Laboratories, St. Paul, USA) was dis-
solved in a 1:1 mixture of ethanol and Cremophor EL
(Sigma-Aldrich, St. Louis, USA) to make a stock solution
of 12 mg/mL. Prior to administration, the paclitaxel so-
lution was further diluted with sterile saline (1:3). Under
isoflurane (2%) anesthesia, rats were administered the
solution via the tail vain on days 0 and 3 after paw with-
drawal threshold was measured. We used a previously
characterized model of paclitaxel-induced peripheral
neuropathy produced by repeated infusions of paclitaxel
at a cumulative dose of 36 mg/kg (2 × 18 mg/kg, 3 days
apart) [9]. Control rats received equivalent volumes of
the Cremophor/ethanol vehicle.
For immunohistochemical experiments, rats were deeply
anesthetized by pentobarbital and perfused transcardially
with phosphate-buffered saline (PBS, composition in mM:
NaCl 137, KCl 2.7, KH2PO4 1.5, NaH2PO4 8.1; pH 7.4)
followed by ice-cold 4% paraformaldehyde/PBS. The L5
segment of the lumbar spinal cord was removed, postfixed
in the same fixative, and placed in 30% sucrose solution
for 24 hr at 4°C. Transverse L5 spinal cord sections
(30 μm) were cut on a Leica CM 1850 cryostat (Leica
Biosystems, Wetzlar, Germany) and incubated for 2 hr
at room temperature in a blocking solution (3% normal
goat serum), and then incubated for 48 hr at 4°C in the
primary antibody for ionized calcium-binding adaptermolecule 1 (Iba1, 1:2000, Wako, Osaka, Japan), a
marker of microglia. Spinal sections were incubated
with secondary antibodies conjugated to Alexa Fluor
488 (1:1000, Life Technologies Japan, Tokyo, Japan) and
mounted in Vectashield containing 4',6-diamidino-2-
phenylindole (DAPI, Vector Laboratories, Burlingame,
USA). Two to three sections from the L5 spinal cord
segments of each rat were randomly selected and ana-
lyzed using an LSM510 Imaging System (Carl Zeiss
Japan, Tokyo, Japan). The numbers of Iba1+ cells in the
SDH (lamina I – IV) were counted.
For quantitative real-time PCR, rats were deeply anes-
thetized with pentobarbital, perfused transcardially with
PBS, and the L5 spinal cord was removed immediately.
The tissues were separated into ventral and dorsal horn.
The sample was homogenized with TRIsure (Bioline,
London, UK) and RNA was purified using an RNeasy mini
plus kit (Qiagen, Valencia, USA). The amount of RNA was
quantified using NanoDrop spectrophotometer (Thermo
Scientific, Wilmington, USA). RNA was transcribed using
PrimeScript Reverse Transriptase (Takara Bio, Otsu,
Japan). Quantitative PCR was performed using Premix Ex
Taq (Takara) together with a 7500 real-time PCR system
(Life Technologies Japan, Tokyo, Japan), and the data were
analyzed using 7500 System SDS Software 1.3.1 (Life
Technologies Japan, Tokyo, Japan). Expression levels of
genes of interest were normalized to the values for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
were expressed as fold change over control rats. The se-
quences of TaqMan primer pairs and probes are described
below: rat Iba1, 5′-GATTTGCAGGGAGGAAAAGCT-3′
(forward), 5′-AACCCCAAGTTTCTCCAGCAT-3′ (reverse),
5′-CAGGAAGAGAGGTTGGATGGGATCAA-3′ (Taqman






3′ (Taqman probe); rat CCR5, 5′-GACCGGGTATA
GACTGAGCTTACAC-3′ (forward), 5′-ACTCTTGG
GATGACACACTGCTGCCTC-3′ (reverse), 5′-CAGG





Mechanical allodynia was assessed using von Frey fila-
ments (North Coast Medical, Gilroy, USA). Rats were
placed in an aluminum cage with a wire mesh grid floor
in a quiet room, 30 min before the start of testing. The
von Frey filament (1.0–15.0 g) was inserted through the
mesh floor bottom and was applied to the middle of the
plantar surface of the hindpaw. The 50% paw withdrawal
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method [16].
For intrathecal administration, under isoflurane (2%)
anesthesia, rats were implanted with a 32-gauge intrathecal
catheter (ReCathCo, Allison Park, USA) through the
atlanto-occipital region into the lumbar enlargement of the
spinal cord. Seven days after implantation, the catheter
placement was verified by the observation of transient
hindpaw paralysis induced by intrathecal injection of lido-
caine (2%, 5 μL). Animals that failed to display paralysis fol-
lowing lidocaine administration were not included in the
experiments. To test for possible effects on the develop-
ment of paclitaxel-induced mechanical allodynia, rats were
injected with a CCL3-neutralizing antibody (4 ng/10 μL;
R&D Systems, Minneapolis, UAS) (or control IgG2A) and
the selective P2X7R antagonist A438079 (1 μg/10 μL,
Tocris Bioscience, Bristol, UK) (or PBS) once a day for
7 days starting from 1 day before the first injection of pacli-
taxel. Intrathecal administration of these drugs was done
soon after the completion of behavioral measurement
(10:00 ~ 12:00). For experiments testing their effects on
maintenance of paclitaxel-induced mechanical allodynia,
these agents were administered intrathecally to paclitaxel-
treated rats, once, on day 7.
Data are expressed as the means ± SEM. Statistical ana-
lyses of the results were conducted with the Student’s t
test, one-way ANOVA with post hoc Dunnett’s multiple
comparisons, and two-way ANOVA with Bonferroni’s
post hoc analysis. The threshold for statistical significance
was set at a P value < 0.05.
Results
First, to confirm mechanical pain hypersensitivity in rats
that had been administered paclitaxel via the dosing regi-
men used in this study, we measured PWT in response to
mechanical stimulation of paclitaxel-treated rats. As
shown in Figure 1A, paclitaxel produced a profound,
long-term decrease in PWT. We next immunohisto-
chemically examined activation of microglia in the SDH
using an antibody against Iba1, a marker of microglia, in
paclitaxel-treated rats. In the L5 SDH of paclitaxel-treated
rats, Iba1 immunofluorescence was clearly increased
(Figure 1B). At high magnification, Iba1-positive microglia
showed an activated morphology such as thickened cell
bodies and retracted processes (Figure 1B insets). The
number of Iba1-positive microglia in the L5 SDH was sig-
nificantly increased on days 7 and 14 after the first injec-
tion of paclitaxel (Figure 1C). In addition, we also
observed a significant increase in the level of mRNA for
Iba1 in the SDH (data not shown). These results together
indicate that microglia become activated in the SDH of
paclitaxel-treated rats.
To examine changes in expression of CCL3 in the SDH,
we performed real-time RT-PCR analysis. Seven days afterthe first paclitaxel injection, the expression of CCL3
mRNA was markedly increased in the SDH (Figure 2A).
The increase in CCL3 mRNA in the SDH was detected as
early as day 3 (but was not statistically significant at this
time), and the highest level was observed on day 7. The
upregulation of CCL3 was still evident, to a slightly lesser
extent, on day 14 (Figure 2A). The time course of CCL3
upregulation paralleled that of the number of microglia in
the SDH (Figure 1C). We also examined the expression of
CCR5 and CCR1 (receptors for CCL3 [14]) mRNAs in the
SDH. CCR5 expression was significantly increased in the
SDH on days 7 and 14 after the first paclitaxel administra-
tion (Figure 2B). By contrast, the CCR1 mRNA expression
level was unchanged at all time points tested (Figure 2C).
To determine the role of spinal CCL3 in paclitaxel-
induced mechanical allodynia, we tested the effect of a
CCL3-neutralizing antibody on the PWT in paclitaxel-
treated rats. Repeated intrathecal injection of an anti-CCL3
antibody [once a day from day 0 (before the first paclitaxel
injection) until day 6] prevented the decrease in PWT in
paclitaxel-treated rats (Figure 3A). We also tested the effect
of a single intrathecal injection of the CCL3 antibody on
day 7 after the first paclitaxel injection, a time correspond-
ing to the highest expression level of CCL3. Intrathecal
CCL3 antibody injection significantly increased the PWT in
paclitaxel-treated rats (Figure 3B). These results indicate
that spinal CCL3 contributes to the development and
maintenance of paclitaxel-induced mechanical allodynia.
We have previously demonstrated that activating puri-
nergic P2X7Rs in cultured microglia causes release of
CCL3. Thus, we further investigated the involvement of
spinal P2X7Rs. We examined expression of P2X7Rs in
the SDH and found that paclitaxel treatment signifi-
cantly increased expression of P2X7R mRNA in the
SDH on day 7. To determine the role of spinal P2X7Rs
in the development of mechanical allodynia, we repeat-
edly administered A438079, a selective antagonist for
P2X7Rs [17,18], into the intrathecal space. As shown in
Figure 4B, repeated intrathecal administration of A438079
prevented the decrease in the PWT in paclitaxel-treated
rats (Figure 4B). We also found that a single intrathecal
administration of A438079 to paclitaxel-treated rats on
day 7 reversed mechanical allodynia (Figure 4C).
Discussion
In the present study, we demonstrated for the first time
that the chemokine CCL3 in the spinal cord is involved in
the mechanical allodynia caused by paclitaxel treatment in
rats. Our behavioral data showing both the preventive and
reversal effects of chronic and single intrathecal adminis-
tration, respectively, of a CCL3-neutralizing antibody on
the paclitaxel-induced allodynia suggest that CCL3 plays
important roles not only in the development of paclitaxel-





















































Figure 1 Administration of paclitaxel causes activation of microglia in the SDH. (A) Threshold for withdrawal in response to mechanical
stimulation to the hindpaw before and after injection of vehicle or paclitaxel (**P < 0.01, *** P < 0.001 vs. vehicle group, n = 6). (B) Immunofluorescence
for Iba1, a marker of microglia, in the SDH of vehicle (control)- or paclitaxel-treated rats (Scale bar, 200 μm). Insets: high magnification images (Scale
bar, 20 μm). (C) The number of microglia labeled with Iba1 per 6 × 105 μm in the SDH of paclitaxel-treated rats (n = 3, **P < 0.01, ***P < 0.001, vs. naïve
control rats). Values are means ± s.e.m.
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pression in the SDH of paclitaxel-treated rats remains to
be determined, the temporal correlation between the up-
regulation of CCL3 expression and the increase in the
number of microglial cells in the SDH leads us to
hypothesize that the CCL3 may be derived from activated
microglia. Indeed, the morphological hypertrophy of
microglia and the increase in the number of microglia,
both of which are major immunohistochemical features of
microglial activation, were evident in the SDH of
paclitaxel-treated rats. Furthermore, our previous study
revealed production and release of CCL3 from cultured
microglia [11]. In a recent study using rat brain slices
in vitro, neuronal injury was shown to induce the
microglial production of CCL3 [19]. We have also re-
cently demonstrated upregulation of CCL3 expression
in spinal microglia after traumatic nerve injury in rats



























































Figure 2 Upregulation of CCL3 and CCR5 mRNAs in the SDH followin
levels for CCL3 (A), and the chemokine receptors CCR1 (B) and CCR5 (C) in th
first injection of paclitaxel (n = 4–6, **P < 0.001 vs. control). Values represent th
in paclitaxel-treated rats to that in naїve control rats (fold change over controP2X7Rs have been implicated in CCL3 release from micro-
glia [11], and our study showed that pharmacological
blockade of spinal P2X7Rs suppressed paclitaxel-
induced mechanical allodynia, the effect of which was
similar to that of the CCL3-neutralizing antibody.
P2X7R expression has been reported to be upregulated
predominantly in microglia in the SDH after traumatic
nerve injury [20,21]. Thus, microglial cells could be a
candidate for the source of CCL3 in the SDH of
paclitaxel-treated rats. However, we can not exclude a
possible involvemen t of other cell types expressing
CCL3 in the SDH. Indeed, in addition to microglia, cul-
tured astrocytes also express CCL3 [22]. Consistent
with previous studies, we also found that paclitaxel
treatment changed the morphology and expression of
GFAP in the SDH (data not shown). Recent studies
have implicated spinal astrocytes in chemotherapy-
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Figure 3 A CCL3-neutralizing antibody suppresses the development and maintenance of paclitaxel-induced mechanical allodynia.
Intrathecal administration of a CCL3-neutralizing antibody (4 ng/10 μL) or control IgG2A was done once a day for 7 days (from a day before the
first paclitaxel injection until day 6) (A) or once on day 7 after the first paclitaxel injection (B) (n = 6, *P < 0.05, **P < 0.01, ***P < 0.001, vs. control
group). Values are means ± s.e.m.
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http://www.molecularpain.com/content/10/1/53The present study showed that a single intrathecal ad-
ministration of either a CCL3-neutralizing antibody or the
selective P2X7R antagonist reversed the established mech-
anical allodynia in paclitaxel-treated rats. Considering that
microglia release CCL3 in response to P2X7R activation
[11], the most parsimonious hypothesis is that ongoing
signaling via CCL3 (presumably released from P2X7R-
stimulating microglia) is crucial for maintaining paclitaxel-
induced pain hypersensitivity. Although the detailed
mechanisms by which CCL3 mediates paclitaxel-induced
mechanical allodynia are not clear, spinal CCL3 might
affect spinal pain processing. The ability of spinal CCL3 to
produce mechanical allodynia has been demonstrated by
our and other studies showing that intrathecal administra-
tion of CCL3 to naïve animals produces pain hypersensi-
tivity in response to mechanical stimulation [12,25]. The














































































Figure 4 P2X7Rs are upregulated by paclitaxel treatment and contrib
mRNA in the SDH of paclitaxel- and vehicle-treated rats 7 days after the first inje
P2X7R mRNA (normalized to the level of GAPDH mRNA) in paclitaxel-treated ra
(a selective P2X7R antagonist; 1 μmol/10 μL) was intrathecally administered onc
(n = 6, ***P < 0.001, vs. vehicle-treated control group). (C) A438079 (1000
*P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle-treated control group). Values areand the time course of its upregulation matched that of
CCL3 expression in the SDH. CCR5 was implicated in pain
hypersensitivity in a model of neuropathic pain caused by
traumatic nerve injury [12,15]. CCR5 expression has been
reported to be localized to activated microgila in the spinal
cord in response to nerve injury [12,26]. It is thus specu-
lated that spinal CCL3 released from microglia in response
to activation of P2X7Rs by extracellular ATP (which is pre-
sumably released from neighboring neurons [27] or glial
cells [28]) further activates microglia via CCR5 in an auto-
crine manner, which may in turn lead to an alteration of
dorsal horn pain processing. On the other hand, there was
a lack of changes in CCR1 expression in the SDH of
pactitaxel-treated rats, although a previous study has re-
ported the upregulation of CCR1 in the spinal cord after
traumatic nerve injury [13]. Considering recent findings
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ute to mechanical allodynia. (A) Real-time RT-PCR analysis of P2X7R
ction of paclitaxel (n = 6, ***P < 0.001). Values represent the relative ratio of
ts to that in vehicle control rats (fold change over control rats). (B) A438079
e a day for 7 days (from a day before the first paclitaxel injection to day 7)
nmol/10 μL) was intrathecally administered once on day 7 (n = 6,
means ± s.e.m.
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http://www.molecularpain.com/content/10/1/53suppress paclitaxel-evoked cold hypersensitivity [29], spinal
CCL3-CCR5 signaling may play an important role in
paclitaxel-induced neuropathic pain. However, how CCL3-
stimulated microglia affect pain processing in the dorsal
horn remains to be determined.
In summary, the present study revealed CCL3 as an im-
portant player in the development and maintenance of
mechanical allodynia following paclitaxel treatment. There-
fore, our findings not only provide evidence for a new
mechanism underlying the pathogenesis of chemotherapy-
induced peripheral sensory neuropathy, but also suggest a
novel therapeutic approach to neuropathic pain.
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